Sterile Injectable Drugs: Global Strategic Business Report

Global Sterile Injectable Drugs Market to Reach $1.3 Trillion by 2030

The global market for Sterile Injectable Drugs estimated at US$596.2 Billion in the year 2022, is projected to reach a revised size of US$1.3 Trillion by 2030, growing at a CAGR of 9.7% over the analysis period 2022-2030. Small Molecule, one of the segments analyzed in the report, is projected to record 9.5% CAGR and reach US$522.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Large Molecule segment is readjusted to a revised 9.9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $181.6 Billion, While China is Forecast to Grow at 9.1% CAGR

The Sterile Injectable Drugs market in the U.S. is estimated at US$181.6 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$213 Billion by the year 2030 trailing a CAGR of 9.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.3% and 7.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

Select Competitors (Total 42 Featured) -

• AstraZeneca PLC
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Pfizer, Inc.
• Science, Inc.

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and the publisher's Research Platform
• Complimentary updates for one year